Mirati Therapeutics Inc.发布了其备受期待的KRAS癌战斗机Adagrasib(MRTX-849)的新数据,与已在营销的竞争,Amgen Inc的Lumakras(Sotorasib)相比,结果不同。with KRAS-G12C non-small-cell lung cancer enrolled in Mirati’s registration-enabling phase II Krystal-1 study. Each had received at least one prior systemic therapy, most with a PD-1/L1 inhibitor following or in combination with chemotherapy.